神経障害性疼痛治療薬市場：タイプ別、治療法別、適応症別、流通別、エンドユーザー別-2025～2030年の世界予測

神経障害性疼痛治療薬市場は、2023年に118億5,000万米ドルと評価され、2024年には129億米ドルに達すると予測され、CAGR 9.93％で成長し、2030年には230億1,000万米ドルに達すると予測されています。

神経障害性疼痛治療薬市場には、体性感覚神経系に影響を及ぼす損傷や疾患によって引き起こされる複雑な症状である神経因性疼痛の治療薬を目的とした医薬品の開発、製造、流通が含まれます。これらの医薬品の必要性は、神経障害性疼痛の原因となる糖尿病、がん、脊椎損傷などの疾患の有病率の増加によって推進されています。主に医療や医療現場で使用され、エンドユーザーは病院、クリニック、在宅介護施設などです。主要成長要因としては、製剤技術の進歩、医療支出の増加、神経障害性疾患とその治療薬に対する意識の高まりなどが挙げられます。個別化医療の発展、より効果的な治療薬のためのバイオテクノロジーの活用、医療インフラが整いつつある発展などに潜在的なビジネス機会があります。しかし、市場は研究開発コストの高さ、厳しい規制の枠組み、現在の薬理学的選択肢の副作用といった限界に直面しています。さらに、理学療法や鍼治療薬のような代替療法が利用可能であり、非侵襲的であることから好む患者もいるため、市場成長の障害となっています。技術革新のための最良のセグメントとしては、より的を絞った効果的な解決策を提供することが期待される生物製剤や遺伝子治療薬があります。バイオテクノロジー企業との提携を模索し、予測モデリングや患者に特化した治療薬レジメンのための人工知能に投資することで、競合優位性が得られる可能性があります。市場競争は非常にダイナミックであり、継続的な研究と新しい治療薬法の導入がその強固な性質を示しています。研究開発に積極的に取り組み、規制の変化に適応する企業は、持続的な成長を達成することができます。全体として、この市場での成功は、神経障害性疼痛に苦しむ患者の複雑なニーズを満たすために、規制要件を遵守しながら迅速な技術革新を行う組織の能力にかかっていると考えられます。

市場力学：急速に進化する神経障害性疼痛治療薬市場の主要市場洞察を公開

神経障害性疼痛治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の神経疾患と糖尿病性神経障害の有病率の増加
  • 神経障害治療薬のための個別化医薬品への大きな嗜好性
  • 高齢者の増加による神経障害性疼痛管理の需要増加
• 市場抑制要因
  • 製品回収と新薬開発コストの高騰
• 市場機会
  • 神経障害性疼痛治療薬のための進行中の臨床検査
  • 神経障害性疼痛専門センターの増加と流通促進への取り組み
• 市場課題
  • 神経障害性疼痛治療薬に関連する副作用

ポーターのファイブフォース：神経障害性疼痛治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、神経障害性疼痛治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経障害性疼痛治療薬市場における外部からの影響の把握

外部マクロ環境要因は、神経障害性疼痛治療薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：神経障害性疼痛治療薬市場における競合情勢の把握

神経障害性疼痛治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：神経障害性疼痛治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経障害性疼痛治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：神経障害性疼痛治療薬市場における成功への道筋を描く

神経障害性疼痛治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で神経疾患と糖尿病性神経障害の罹患率が増加
    • 神経障害治療薬における個別化医薬品の大きな好み
    • 高齢者の増加により神経障害性疼痛管理の需要が高まる
  • 抑制要因
    • 製品回収と新薬開発の高コスト
  • 機会
    • 神経障害性疼痛治療薬のための臨床検査が進行中
    • 神経障害と疼痛の専門センターの増加と流通促進の取り組み
  • 課題
    • 神経障害性疼痛治療薬に関連する副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 神経障害性疼痛治療薬市場：タイプ別

• イントロダクション
• 幻肢痛
• 帯状疱疹後神経痛
• 外傷後神経障害
• 三叉神経痛

第7章 神経障害性疼痛治療薬市場：治療薬法別

• イントロダクション
• 抗うつ薬タイプ
  • セロトニンノルアドレナリン
  • 三環系抗うつ薬
• マルチモーダルセラピー
• NSAIDsタイプ
  • イブプロフェン
  • ナプロキセン

第8章 神経障害性疼痛治療薬市場：適応症別

• イントロダクション
• 糖尿病性神経障害
• 脊柱管狭窄症

第9章 神経障害性疼痛治療薬市場：流通別

• イントロダクション
• オンライン薬局
• 小売薬局・ドラッグストア

第10章 神経障害性疼痛治療薬市場：エンドユーザー別

• イントロダクション
• クリニック
• 病院

第11章 南北アメリカの神経障害性疼痛治療薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の神経障害性疼痛治療薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの神経障害性疼痛治療薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Eli Lilly、非オピオイド薬でコンフォセラピューティクスと6億3,000万米ドルの契約を締結神経障害性疼痛治療薬
  • 神経障害性疼痛管理のためのAFD-NP製品の発売
  • Akelos、神経障害性疼痛の非オピオイド代替薬の調査継続のためNIH助成金を受領
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• Aptinyx Inc.
• Assertio Holdings, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Axsome Therapeutics, Inc.
• Bausch Health Companies Inc.
• Baxter International Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• CARA THERAPEUTICS, INC.
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Grunenthal Group
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Scilex Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Trevena Inc.
• Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
• FIGURE 2. NEUROPATHIC PAIN DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEUROPATHIC PAIN DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 93. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 94. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 96. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 101. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 103. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 149. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 155. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 156. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 162. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 163. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 175. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 178. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 185. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 191. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 192. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 199. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 205. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 206. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 212. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 213. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 220. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 221. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 223. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 224. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 227. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 232. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 233. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 234. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 240. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 241. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 245. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 247. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 248. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 249. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 250. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 251. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 252. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 253. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 254. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 255. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 256. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 257. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 258. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 259. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 260. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 261. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 262. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 266. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 267. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 268. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 269. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 273. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 274. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 275. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 276. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 281. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 282. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 283. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 287. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 288. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 289. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 290. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 291. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 294. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 295. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 296. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 297. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 298. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 299. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 301. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 302. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 303. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 304. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 305. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 306. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 308. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 309. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 310. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 311. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 312. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 313. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 315. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 316. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 317. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 318. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 319. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 320. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 322. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 323. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Neuropathic Pain Drug Market was valued at USD 11.85 billion in 2023, expected to reach USD 12.90 billion in 2024, and is projected to grow at a CAGR of 9.93%, to USD 23.01 billion by 2030.

The neuropathic pain drug market encompasses the development, manufacturing, and distribution of pharmaceuticals aimed at treating neuropathic pain, a complex condition caused by damage or disease affecting the somatosensory nervous system. The necessity for these drugs is propelled by the growing prevalence of conditions such as diabetes, cancer, and spinal injuries that contribute to neuropathic pain. They are applied primarily in healthcare and medical settings, with end-users being hospitals, clinics, and homecare setups. Key growth influencers include technological advancements in drug formulation, increased healthcare expenditures, and rising awareness about neuropathic conditions and their drug treatments. Potential opportunities lie in the development of personalized medicine, leveraging biotechnology for more effective treatments, and exploring untapped markets in developing regions with emerging healthcare infrastructures. However, the market faces limitations such as high research and development costs, stringent regulatory frameworks, and side effects of current pharmacological options. Additionally, market growth is challenged by the availability of alternative therapies like physiotherapy and acupuncture, which some patients prefer due to their non-invasive nature. Best areas for innovation include biologics and gene therapy, which hold promise in offering more targeted and effective solutions. Exploring partnerships with biotechnology firms and investing in artificial intelligence for predictive modeling and patient-specific treatment regimens could provide competitive advantages. The neuropathic pain drug market is highly dynamic and competitive, characterized by ongoing research and the introduction of new therapies which indicate its robust nature. Companies that proactively engage in research and development and adapt to regulatory changes are positioned to achieve sustainable growth. Overall, success in this market will likely hinge on an organization's ability to innovate rapidly while maintaining compliance with regulatory requirements, thereby meeting the complex needs of patients suffering from neuropathic pain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuropathic Pain Drug Market

The Neuropathic Pain Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of neurological disorders and diabetic neuropathy worldwide
  • Significant preference for personalized medicines for neuropathic treatment
  • Increase in the geriatric population raises the demand for neuropathic pain management
• Market Restraints
  • Product recall and high cost of new drug development
• Market Opportunities
  • Ongoing clinical trial for neuropathic pain treatment
  • Rising number of specialty neuropathy and pain centers and efforts to boost distribution
• Market Challenges
  • Side effects associated with neuropathic pain drug

Porter's Five Forces: A Strategic Tool for Navigating the Neuropathic Pain Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuropathic Pain Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuropathic Pain Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuropathic Pain Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuropathic Pain Drug Market

A detailed market share analysis in the Neuropathic Pain Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuropathic Pain Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuropathic Pain Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuropathic Pain Drug Market

A strategic analysis of the Neuropathic Pain Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathic Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Aptinyx Inc., Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Axsome Therapeutics, Inc., Bausch Health Companies Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, CARA THERAPEUTICS, INC., Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline PLC, Grunenthal Group, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Trevena Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Neuropathic Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.
• Based on Treatment, market is studied across Antidepressant Drugs Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
• Based on Indication, market is studied across Diabetic Neuropathy and Spinal Stenosis.
• Based on Distribution, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
• Based on End User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of neurological disorders and diabetic neuropathy worldwide
    • 5.1.1.2. Significant preference for personalized medicines for neuropathic treatment
    • 5.1.1.3. Increase in the geriatric population raises the demand for neuropathic pain management
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall and high cost of new drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing clinical trial for neuropathic pain treatment
    • 5.1.3.2. Rising number of specialty neuropathy and pain centers and efforts to boost distribution
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with neuropathic pain drug
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neuropathic Pain Drug Market, by Type

• 6.1. Introduction
• 6.2. Phantom Limb Pain
• 6.3. Post Herpetic Neuralgia
• 6.4. Post-traumatic Neuropathy
• 6.5. Trigeminal Neuralgia

7. Neuropathic Pain Drug Market, by Treatment

• 7.1. Introduction
• 7.2. Antidepressant Drugs Type
  • 7.2.1. Serotonin Noradrenaline
  • 7.2.2. Tricyclic Antidepressants
• 7.3. Multimodal Therapy
• 7.4. NSAIDs Type
  • 7.4.1. Ibuprofen
  • 7.4.2. Naproxen

8. Neuropathic Pain Drug Market, by Indication

• 8.1. Introduction
• 8.2. Diabetic Neuropathy
• 8.3. Spinal Stenosis

9. Neuropathic Pain Drug Market, by Distribution

• 9.1. Introduction
• 9.2. Online Pharmacies
• 9.3. Retail Pharmacies & Drug Stores

10. Neuropathic Pain Drug Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Hospitals

11. Americas Neuropathic Pain Drug Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Neuropathic Pain Drug Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Neuropathic Pain Drug Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Eli Lilly strikes USD 630 million deal with Confo Therapeutics for non-opioid neuropathic pain drug
  • 14.3.2. Launch of AFD-NP Product For Neuropathic Pain Management
  • 14.3.3. Akelos Receives NIH Grant To Continue Research On Nonopioid Alternative For Neuropathic Pain
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Amgen Inc.
• 4. Aptinyx Inc.
• 5. Assertio Holdings, Inc.
• 6. Astellas Pharma Inc.
• 7. AstraZeneca PLC
• 8. Axsome Therapeutics, Inc.
• 9. Bausch Health Companies Inc.
• 10. Baxter International Inc.
• 11. Biogen Inc.
• 12. Bristol-Myers Squibb Company
• 13. CARA THERAPEUTICS, INC.
• 14. Daiichi Sankyo Company, Limited
• 15. Eli Lilly and Company
• 16. GlaxoSmithKline PLC
• 17. Grunenthal Group
• 18. Johnson & Johnson Services Inc.
• 19. Merck & Co., Inc.
• 20. Novartis AG
• 21. Pfizer Inc.
• 22. Regeneron Pharmaceuticals Inc.
• 23. Scilex Pharmaceuticals
• 24. Teva Pharmaceutical Industries Ltd.
• 25. Trevena Inc.
• 26. Vertex Pharmaceuticals Incorporated